Ozempic’s hidden pregnancy risk few women know about

A groundbreaking study spearheaded by Flinders University researchers has revealed a critical oversight in the burgeoning use of GLP-1 receptor agonists, a class of medications increasingly popular for weight loss, among women of reproductive age in Australia. The research indicates that a vast majority of these women are not employing effective contraception, despite well-established warnings regarding the potential risks to pregnancy and unborn babies. This alarming gap in clinical practice and patient awareness underscores a significant public health challenge, necessitating urgent revisions to prescribing guidelines and patient counselling protocols.

Alarming Gap in Contraception Use Among GLP-1 Users Highlighted

The core findings, published in the esteemed Medical Journal of Australia, draw from a comprehensive analysis of over 1.6 million women aged 18 to 49 who attended general practices across Australia between 2011 and 2022. Of the 18,010 women identified as having been newly prescribed GLP-1 receptor agonists during this period, a concerning statistic emerged: only 21% had a recorded history of using contraception at the time of their prescription. This stark figure highlights a systemic failure to integrate reproductive health considerations into the routine management of patients initiating these potent medications.

Associate Professor Luke Grzeskowiak, a pharmacist and lead author from Flinders University’s College of Medicine and Public Health, expressed profound concern over the findings. "We’re witnessing widespread use of these medications among women of childbearing age, yet there’s very little evidence that contraception is being considered as part of routine care," Grzeskowiak stated. He underscored the dual nature of these drugs, acknowledging their efficacy while cautioning, "These medications can be incredibly helpful, but they’re not risk-free, especially during pregnancy."

The study further identified that 2.2% of women became pregnant within six months of commencing GLP-1 treatment. The highest rates of unintended pregnancies were observed among younger women with a diabetes diagnosis, as well as among women in their early thirties who did not have diabetes but were likely prescribed the medication for weight management. Notably, women diagnosed with polycystic ovary syndrome (PCOS) were twice as likely to conceive, a finding that suggests the weight-loss benefits of GLP-1s may inadvertently improve fertility, thereby amplifying the need for robust contraceptive planning. Crucially, the data unequivocally demonstrated that women who were using contraception at the time of prescribing exhibited a significantly lower risk of pregnancy, reinforcing the preventative power of effective birth control.

The Rise of GLP-1 Receptor Agonists: From Diabetes Management to Weight Loss Phenomenon

The journey of GLP-1 receptor agonists (Glucagon-Like Peptide-1) began in the early 2000s, with the first drug in this class, exenatide (Byetta), approved by the U.S. Food and Drug Administration (FDA) in 2005 for the treatment of type 2 diabetes. These medications work by mimicking the action of the natural hormone GLP-1, which is released in response to food intake. They stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, leading to better glycemic control and, as a significant side effect, weight loss.

Over the past two decades, the class has expanded to include long-acting formulations like liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and perhaps most notably, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). While initially a cornerstone for managing type 2 diabetes, the substantial weight-loss benefits observed in clinical trials led to their approval for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. For instance, liraglutide was approved for weight management in 2014, followed by semaglutide (Wegovy) in 2021.

The global phenomenon often dubbed the "Ozempic effect" has dramatically propelled these drugs into the public consciousness, transforming them from niche diabetes treatments into highly sought-after weight-loss solutions. This surge in popularity has led to an unprecedented demand, frequently outstripping supply and resulting in widespread "off-label" prescribing, where physicians prescribe a drug for an indication not officially approved by regulatory bodies like the Therapeutic Goods Administration (TGA) in Australia. The Flinders University study vividly illustrates this trend, finding that in 2022 alone, over 6,000 women initiated GLP-1 treatment, and more than 90% of these individuals did not have a diabetes diagnosis, indicating their primary use was for weight loss. The global market for GLP-1 agonists is projected to reach hundreds of billions of dollars in the coming years, underscoring their profound impact on healthcare and public health.

Australian Study Uncovers Critical Data Deficiencies

The comprehensive nature of the study, leveraging de-identified patient data from Australian general practices, provides a robust snapshot of real-world prescribing patterns and patient outcomes. The dataset, encompassing records from 2011 to 2022, allowed researchers to track prescriptions, contraception use, and pregnancy occurrences over a significant period. This longitudinal approach is critical for identifying trends and assessing the effectiveness of current clinical practices.

The 21% contraception rate among women starting GLP-1s is particularly stark when viewed against the backdrop of established medical advice. Reproductive-aged women are broadly defined as those between 15 and 49 years old, a demographic group where unintended pregnancies are a persistent public health concern. The study’s focus on women aged 18-49 directly targets this vulnerable cohort. The relatively high pregnancy rate of 2.2% within six months of starting treatment, while seemingly small, translates to hundreds of potential pregnancies across the studied population. Given the scale of GLP-1 prescriptions globally, this percentage represents a significant number of individuals potentially exposed to unknown risks.

The finding that women with PCOS were twice as likely to conceive adds another layer of complexity. PCOS is a common endocrine disorder affecting up to 10-15% of women of reproductive age, often characterized by insulin resistance, obesity, and infertility. The weight-loss benefits of GLP-1s could inadvertently restore ovulatory function and fertility in these women, making contraception even more crucial. This highlights a powerful, yet often overlooked, interaction between metabolic health improvements and reproductive outcomes. The study’s clear demonstration that effective contraception significantly lowers pregnancy risk underscores that the problem is not an inherent failure of contraception, but rather a failure in its consistent implementation and counselling.

International Precedents and Emerging Concerns

The concerns raised by the Flinders study are not isolated. International medical bodies and regulatory agencies have been grappling with the implications of GLP-1 use during pregnancy. A previous review of animal studies conducted by the University of Amsterdam, for instance, has linked GLP-1 exposure during gestation to adverse fetal outcomes, including reduced fetal growth and skeletal abnormalities. While these studies primarily involved rodents and non-human primates, and direct extrapolation to humans requires caution, they provide a crucial signal of potential teratogenicity. For example, some studies in rats and rabbits have shown increased rates of visceral and skeletal malformations, and early embryonic deaths at higher doses.

Regulatory agencies globally have responded with warnings. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) explicitly advises that women using GLP-1 receptor agonists should avoid pregnancy and employ effective contraception. Similar warnings are present in product information leaflets from manufacturers worldwide. The TGA in Australia also advises against the use of these medications during pregnancy due to insufficient human data and concerns from animal studies. Despite these clear guidelines and warnings, the Flinders study indicates a significant disconnect between official recommendations and actual clinical practice in Australia.

This disparity suggests a potential gap in prescriber awareness, patient education, or the integration of reproductive health screening into the GLP-1 prescription pathway. The rapid increase in off-label prescribing for weight loss, often driven by patient demand and media attention, may have outpaced the consistent application of established safety protocols.

Calls for Urgent Action: Strengthening Clinical Guidelines and Patient Education

The findings of the Flinders University study serve as an urgent call to action for the Australian healthcare system and potentially for other nations facing similar trends. Associate Professor Grzeskowiak emphasized the need for a fundamental shift in clinical practice: "We need to ensure that reproductive health is part of every conversation when these drugs are prescribed to any women of childbearing age." This implies a more holistic approach to patient care, where the long-term reproductive plans and risks are thoroughly discussed alongside the benefits of weight loss or diabetes management.

Medical bodies, such as the Royal Australian College of General Practitioners (RACGP) and the Australian Medical Association (AMA), are expected to reinforce the importance of comprehensive patient counselling. This would involve explicit discussions about the risks of GLP-1s in pregnancy, the necessity of effective contraception, and the potential for increased fertility, particularly in conditions like PCOS. Furthermore, clearer, more robust practice recommendations and guidelines for prescribers are vitally important to ensure the safe and effective use of GLP-1s. These guidelines should ideally include mandatory checklists or decision-support tools for clinicians when prescribing to women of reproductive age.

Pharmaceutical companies, while providing product information that warns against use in pregnancy, also have a role in supporting educational initiatives for healthcare professionals regarding responsible prescribing and patient counselling. Pharmacists, often the last point of contact before medication dispensing, are also critical in reinforcing these messages and ensuring patient understanding.

Broader Public Health and Ethical Implications

The implications of the study extend beyond individual patient safety to broader public health and ethical considerations. A significant number of unintended pregnancies occurring while on GLP-1s could lead to a cohort of fetuses potentially exposed to adverse effects, necessitating increased vigilance for congenital anomalies and developmental issues. This places additional strain on obstetric and paediatric services.

Ethically, the principle of informed consent is paramount. Patients must be fully aware of all potential risks and benefits, including those related to reproductive health, before commencing treatment. The current data suggests a potential deficit in this informed consent process for many women. Physicians bear a significant responsibility to proactively engage in these discussions, ensuring that the desire for weight loss does not overshadow the critical importance of reproductive planning.

The study also highlights the complex interplay between the global obesity epidemic, fertility, and pharmaceutical interventions. While GLP-1s offer a powerful tool in combating obesity and its associated health risks, their growing use underscores the need for continuous vigilance and adaptation of clinical practice guidelines. The potential for these medications to improve fertility in women struggling with conditions like PCOS, while beneficial in some contexts, creates a paradoxical situation where increased fertility, if unintended and unmanaged, can lead to adverse pregnancy outcomes. This necessitates a nuanced approach to patient counselling that acknowledges both the desired and unintended effects of treatment.

Further studies evaluating the direct impact of these medications on human pregnancy and unborn babies are critically warranted. These prospective registries and observational studies would provide much-needed human data to either confirm or refute the animal study findings and inform future clinical guidelines with greater certainty.

Navigating the Future of Weight Management: Balancing Benefits and Risks

In conclusion, the Flinders University research provides a timely and essential warning about the potential reproductive health risks associated with GLP-1 receptor agonists. While these medications represent a significant advancement in the management of type 2 diabetes and obesity, their widespread adoption, particularly for weight loss, demands a heightened level of clinical scrutiny and patient education. The advice remains clear: individuals considering or currently taking GLP-1 medicines should engage in a thorough discussion with their general practitioner about the risks and benefits, ensuring that reproductive health and contraception are central to that conversation. Only by fostering a culture of informed decision-making and adhering to robust clinical guidelines can the healthcare community harness the benefits of these powerful drugs while safeguarding the health of mothers and their unborn children.

Acknowledgements: Luke Grzeskowiak receives salary support from a Channel 7 Children’s Research Foundation Fellowship (CRF-210323). We also acknowledge the contributions of members of the SPHERE Centre of Research Excellence in Women’s Sexual and Reproductive Health in Primary Care (SPHERE 2.0 CRE), which is funded by the National Health and Medical Research Council (APP2024717).